News

EconomyNov 13, 2026

Ghana to invest US$1bn in domestic pharmaceutical production

Ghana GuardianSource

**Ghana plans to invest US1billioninmedicineproductionandbiomanufacturingasitseekstoreduceitsrelianceonimporteddrugsandestablishitselfasapharmaceuticalhubinWestAfrica.∗∗FinanceMinisterDrCassielAtoForsonannouncedtheplanswhilepresentingthe2027BudgetStatementandEconomicPolicytoParliamentonThursday,November12,2026.Theinvestmentformspartofthegovernment’sNewEconomyagendaandcomesalongsideanallocationofGH¢28billiontothe“BigPush”Programme.Ghanacurrentlyimportsbetween70and75percentofthemedicinesitneeds,atanannualcostofaboutUS1 billion in medicine production and biomanufacturing as it seeks to reduce its reliance on imported drugs and establish itself as a pharmaceutical hub in West Africa.** Finance Minister Dr Cassiel Ato Forson announced the plans while presenting the 2027 Budget Statement and Economic Policy to Parliament on Thursday, November 12, 2026. The investment forms part of the government’s New Economy agenda and comes alongside an allocation of GH¢28 billion to the “Big Push” Programme. Ghana currently imports between 70 and 75 per cent of the medicines it needs, at an annual cost of about US500 million, according to Dr Forson. He said those imports were placing pressure on the country’s foreign exchange reserves while restricting the expansion of domestic pharmaceutical companies. “We will invest US$1 billion to strengthen medicine security, create skilled industrial work, conserve foreign exchange and build a pharmaceutical export platform for West Africa,” Dr Forson told Parliament. The funding will support the creation of Pharmaceutical and Biomanufacturing Hubs in the Eastern and Central Regions. Qualified Ghanaian and international pharmaceutical companies will be allowed to operate from the facilities under transparent lease and operating agreements. ### Local medicines to receive procurement preference The government also plans to change public procurement laws so locally manufactured medicines become the preferred choice for public institutions when they are available in sufficient quantities and meet approved quality standards. “Ghanaian-produced medicines will become the default choice for every cedi of public money spent on medicines,” Dr Forson said. The policy is intended to use public procurement to strengthen local businesses and increase demand for products made in Ghana. Companies will, however, have to satisfy strict regulatory and manufacturing requirements before they can benefit. Suppliers must be registered with the Food and Drugs Authority (FDA) and comply with Good Manufacturing Practice requirements. The government will also help domestic pharmaceutical companies pursue World Health Organisation (WHO) prequalification, a step intended to improve their ability to compete in international markets. Dr Forson said the preference for locally produced medicines would not shield manufacturers whose products failed to meet required standards or whose performance was inadequate. “Local preference will never excuse poor quality, late delivery or bad value,” he told Parliament. The proposed investment and procurement reforms are intended to strengthen Ghana’s medicine security, reduce the amount of foreign exchange spent on imports and create skilled industrial employment. The government also expects the measures to support the development of a pharmaceutical manufacturing and export centre serving West Africa.

Comments (0)

No comments yet. Be the first to share your thoughts!

Anonymous

Initializing... Please wait while we load your data.
Ghana to invest US$1bn in domestic pharmaceutical production | Economy News